NVTA - Invitae Corporation : US

แหล่งรวบรวมข้อมูลของหุ้นประเทศ All for one, one for global
(ช่วงทดลองเปิดตัว สมาชิกและทุกท่านสามารถเข้าได้ตลอด)
Post Reply
PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Nov 25, 2020 11:05 pm

บริษัทนี้ตรวจdna,genetic กับผู้บริโภคทั่วไป ลองเข้าไปเล่นในwebsiteดูได้ครับ https://www.invitae.com/en

กองarkถือหุ้นใหญ่อยู่คาดว่าอนาคตคงโตได้อีกเยอะ คนน่าจะหันมาตรวจกันมากขึ้นเพื่อรู้ว่าเรามีความเสี่ยงอะไรบ้างครับ



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Fri Dec 11, 2020 10:01 am




PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Fri Dec 11, 2020 10:01 am


SAN FRANCISCO, Dec. 9, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced three studies demonstrating the benefits of genetic testing for all breast cancer patients, impacting treatment decisions and cancer screening for patients and their families. The studies, which will be presented at the 2020 San Antonio Breast Cancer Symposium (SABCS), add to the evidence supporting universal access to genetic information for all breast cancer patients.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue Dec 29, 2020 10:59 am




User avatar
mr.bullish
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 132
Joined: Wed Aug 16, 2017 8:30 am

Re: NVTA - Invitae Corporation : US

Posts by mr.bullish » Tue Dec 29, 2020 4:14 pm

top 10 holdings ของ ARKG ครับ ที่ Cathie Wood คาดว่าจะเป็นปีแห่ง gene editing และ therapeutic

ฝากติดตาม เพจลงทุนหุ้นจีน หุ้นต่างประเทศเพิ่มเติม ที่เพจ ขงเบ้ง ลงทุน ครับ

https://www.facebook.com/kongminginvest


PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Tue Dec 29, 2020 9:23 pm

SAN FRANCISCO, Dec. 29, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a virtual breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
More
The 2021 J.P. Morgan Healthcare Conference is being held virtually via webinar. A live webcast of both the presentation and the breakout session may be accessed at the following direct link or by visiting the investors section of the company's website at ir.invitae.com.

Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and breakout session on the investors section of the company's website at ir.invitae.com.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Mon Jan 11, 2021 7:36 pm

January 11, 2021
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume

-- Presenting at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific --
SAN FRANCISCO, Jan. 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2020 results, reporting strong growth in volume and revenue, signaling continued momentum into 2021.

Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)
"We are very pleased by the acceleration of our business in 2020, particularly in light of the impact of the COVID-19 pandemic on the healthcare system throughout the year," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. "Our results underscore the strength of our customer relationships, our continued ability to execute and the benefits of the investments we've made in expanding our menu, services and platform. The growth in testing during this time of unrelenting stress on the healthcare system further demonstrates the expanding value genetic information is providing patients as they and their physicians face health challenges and decisions."

Preliminary, unaudited financial results and other metrics for 2020

Generated revenue of more than $278 million in 2020, an approximate 28% increase from $217 million in 2019
Reported billable volume of more than 655,000 in 2020, an approximate 40% increase from billable volume of 469,000 in 2019
Announced year-end 2020 cash, cash equivalents, restricted cash and marketable securities of more than $360 million as of December 31, 2020
Outlook for 2021
Looking ahead to 2021 and factoring in the continued impact associated with the COVID-19 pandemic, Invitae reiterates its stated outlook for revenue growth targets of 50% - 60% annual growth over the next few years consistent with its view at the time of the announcement of the ArcherDX acquisition. Invitae anticipates generating revenue in excess of $450 million in 2021.

"We are confident we will continue growing rapidly in 2021, even as we navigate the continued pressure the pandemic is placing on clinicians," said Dr. George. "Our momentum coming out of 2020 and the underlying strength and breadth of our platform enable us to recognize and overcome these challenges while continuing to drive the acceleration of the adoption of genetics in mainstream medicine as the new standard of care."

Invitae has not completed preparation of its financial statements for the fourth quarter or full year 2020. The preliminary, unaudited results presented in this press release for the year ended December 31, 2020 are based on current expectations and are subject to adjustment. Actual results may differ materially from those disclosed in this press release. Invitae will report its full financial results and other metrics during its fourth quarter and year-end 2020 conference call in February.

Invitae's Presentation at 39th Annual J.P. Morgan Healthcare Conference
Invitae will present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. Eastern/7:50 a.m. Pacific. Following the company presentation, management will participate in a breakout session at 11:10 a.m. Eastern/8:10 a.m. Pacific. The 2021 J.P. Morgan Healthcare Conference is being held virtually via webinar. A live webcast of both the presentation and the breakout session may be accessed at the following direct link or by visiting the investors section of the company's website at ir.invitae.com. Public listeners can access an audio and slide recording of the session, which will be available shortly after the conclusion of the presentation and breakout session on the investors section of the company's website at ir.invitae.com.



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Jan 13, 2021 10:47 pm

MENLO PARK, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB), a leading provider of high-quality, long-read sequencing platforms, today announced a multi-year collaboration with Invitae Corporation (NYSE: NVTA), a leading medical genetics company, to begin development of a production-scale high-throughput sequencing platform leveraging the power of PacBio’s highly accurate HiFi sequencing to expand Invitae’s whole genome testing capabilities.

“Whole genome sequencing has the ability to significantly improve diagnosis for a wide range of diseases and guide healthcare throughout life. This collaboration is aimed at developing the technology to make it affordable and accessible to all patients who can benefit from in-depth, full genome information," said Sean George, co-founder and Chief Executive Officer of Invitae. “Our work with PacBio to date has demonstrated the increased diagnostic yield and clinical utility of using information from high-quality, long-read genomes to guide patient care. We believe this world-class sequencing technology combined with our clinical capabilities will uniquely position us to deliver those benefits cost effectively at scale. We look forward to working with the PacBio team to develop a new generation of innovative whole genome-based offerings.”

Identifying the many underlying genetic influences on human health is becoming increasingly critical to overall clinical care and prognosis and whole genome sequencing offers the most comprehensive view of medically relevant variations. As whole genome sequencing continues to grow into a preferred method for genetic testing, it is expected by the Global Alliance for Genomics and Health that by 2025 as many as sixty million genomes will be sequenced. With the development of a new sequencing platform, Invitae and PacBio aim to enable a new class of cost-effective assays that could be used to accelerate the accessibility of a more comprehensive whole genome sequencing approach in areas including carrier screening, immune system response, and other heritable diseases.

“Invitae is a leader in medical genetic testing and has driven innovation in this area for more than a decade. We are excited to join forces to develop and implement this new platform which is built on our shared vision that broad access to whole genome sequencing in the clinic has the power to improve diagnosis and access to precision therapies,” said Christian Henry, President and Chief Executive Officer of Pacific Biosciences. “Building on the proven performance of our HiFi sequencing, we believe that this new system will ultimately enable us to deliver the most clinically relevant whole genome at substantially less than $1,000 which we believe is a critical price threshold needed to expand adoption in routine medical care.”

PacBio HiFi sequencing combines the high accuracy of Sanger sequencing (>99.9%) with long reads up to 25 kb. Together, the length and accuracy of HiFi reads provide excellent detection of variants from single nucleotide changes to large structural variants, even in hard-to-sequence regions of the genome.

Through the collaboration, both companies will commit significant resources to support development of a production-scale sequencing platform designed with the capacity to process clinical whole genomes at scale. Those resources are expected to include talent, technology and collaborative oversight, and Invitae will also invest capital to support development throughout the multi-year effort.



User avatar
mr.bullish
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 132
Joined: Wed Aug 16, 2017 8:30 am

Re: NVTA - Invitae Corporation : US

Posts by mr.bullish » Sun Jan 17, 2021 7:46 pm

phpBB [video]


กองนี้ fund of fund อธิบายภาษาไทยเข้าใจง่ายดีครับ
มี invitae ด้วย

ฝากติดตาม เพจลงทุนหุ้นจีน หุ้นต่างประเทศเพิ่มเติม ที่เพจ ขงเบ้ง ลงทุน ครับ

https://www.facebook.com/kongminginvest


PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Wed Jan 20, 2021 10:36 pm

Update Major shareholder



PK-TYW
สมาชิกสมาคมนักลงทุนเน้นคุณค่า
Posts: 1977
Joined: Thu Feb 21, 2013 4:00 pm

Re: NVTA - Invitae Corporation : US

Posts by PK-TYW » Fri Jan 22, 2021 10:28 am

SAN FRANCISCO, Jan. 21, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 7,766,990 shares of its common stock at a price to the public of $51.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $400.0 million. The offering is expected to close on or about January 26, 2021, subject to customary closing conditions. In addition, Invitae has granted the underwriters a 30-day option to purchase up to an additional 1,165,048 shares of its common stock at the public offering price, less underwriting discounts and commissions.



Post Reply